Answers to Reasoning Questions (Immunology/Microbiology)

1. Why does a booster dose produce a faster and stronger immune response than the primary dose? (JNM)

The primary dose activates naive B and T lymphocytes, which must first undergo clonal selection, proliferation, and differentiation before antibody is produced - a slow process with a long lag phase, dominated by low-affinity IgM.

A booster (secondary) dose re-exposes the antigen to a large pool of memory B and T cells already generated and expanded from the primary response. These memory cells are long-lived, present in greater numbers, have undergone affinity maturation (higher-affinity receptors), and require a much shorter activation time. This produces the anamnestic response: a shorter lag phase, higher peak antibody titer, predominantly high-affinity IgG, and a more sustained response (Medical Microbiology 9e, p. TIME COURSE OF ANTIBODY RESPONSE; Park's PSM).

2. Antibody and antigen excess can lead to false negative reactions (CIMS)

This is the prozone/hook effect, seen in agglutination and sandwich immunoassays (e.g., ELISA, latex agglutination).

Antibody excess (prozone): too many antibody molecules relative to antigen prevent lattice/cross-link formation - each antigen is coated by antibody without bridging between particles, so visible agglutination fails to occur.
Antigen excess (hook effect): in sandwich assays, excess antigen saturates both the capture and labeled/detection antibodies independently, so the antigen is never "sandwiched" between the two antibodies, giving a falsely low or negative signal despite very high analyte concentration.

Both are avoided by serial dilution of the test sample, which restores the antigen:antibody ratio to the zone of equivalence where lattice formation is optimal (Henry's Clinical Diagnosis and Management by Laboratory Methods, p. Antibody-Antigen Interaction; Tietz Textbook of Laboratory Medicine).

3. Why is ELISA preferred over Rapid test as the confirmatory test for HIV? Principle (Jagdalpur)

ELISA is preferred because it has higher sensitivity and specificity, is quantitative/semi-quantitative (measured by optical density against a cut-off), allows batch testing of large sample numbers economically, has built-in positive/negative controls for quality assurance, and can detect lower antibody/antigen concentrations than a rapid immunochromatographic test, reducing false negatives during window-period or early seroconversion. Rapid tests are qualitative, point-of-care, less standardized, and more prone to reader-dependent error, so they are used for screening, while ELISA (or a repeat ELISA/Western blot) is used for confirmation per WHO/NACO strategy.

Principle: ELISA is a solid-phase immunoassay. A microtiter well is coated with a known antigen (or antibody). The patient's serum is added; if specific antibody is present, it binds the fixed antigen. After washing away unbound material, an enzyme-labeled anti-human antibody (conjugate) is added, which binds to the captured antibody. A chromogenic substrate is then added; the enzyme converts it to a colored product. Color intensity (read by spectrophotometer as optical density) is directly proportional to the amount of antibody present in the sample (Janeway's Immunobiology 10e, ELISA/RIA section).

4. What is C-reactive protein (CRP)? Clinical applications in microbiology (Kanker)

CRP is an acute-phase plasma protein synthesized by the liver in response to IL-6 (and IL-1, TNF-α) released during tissue injury or infection. It binds phosphocholine on microbial cell walls and damaged cell membranes, activating the classical complement pathway and promoting opsonization and phagocytosis.

Clinical applications:

Marker of acute bacterial infection/inflammation - rises within 6-8 hours, much faster than ESR
Differentiates bacterial (markedly raised CRP) from viral infection (mildly raised)
Monitors response to antibiotic therapy - falling CRP indicates treatment success
Used to detect post-operative or intra-abdominal sepsis, neonatal sepsis, and to guide duration of antibiotics
Non-specific acute-phase reactant used with other markers (procalcitonin) in sepsis workup and also used in cardiovascular risk stratification (Firestein & Kelley's Rheumatology; Fuster and Hurst's The Heart)

5 & 10. Why is BCG not given to immunocompromised children? (Mahasamund / AIMMMCR)

BCG is a live attenuated vaccine (Mycobacterium bovis). In an immunocompetent host, the attenuated organism is contained and cleared by intact cell-mediated immunity. In immunocompromised children (HIV infection, SCID, on immunosuppressive therapy, or malnourished with cellular immune deficiency), the weakened T-cell/macrophage response cannot contain even the attenuated organism, leading to uncontrolled local or disseminated BCG infection (BCGosis) - a rare but often fatal complication (approximately 2 per million vaccinated, but far higher in the severely immunocompromised). Hence live vaccines like BCG are contraindicated in immunocompromised persons and pregnant women; killed/subunit vaccines are used instead (Murray & Nadel's Textbook of Respiratory Medicine; Red Book 2021; Medical Microbiology 9e).

6 & 14. Complement pathways / Biological role of complement (Ambikapur / SRIMSR)

Three activation pathways converge on C3 to generate C3 convertase and the membrane attack complex (MAC, C5b-9):

Classical pathway: triggered by antigen-antibody (IgM or IgG) immune complexes binding C1q, activating C1r/C1s, which cleave C4 and C2 to form C4b2a (C3 convertase).
Alternative pathway: triggered directly by microbial surfaces (LPS, fungal cell walls) via spontaneous "tick-over" hydrolysis of C3, Factor B and Factor D, stabilized by properdin, forming C3bBb (C3 convertase) - antibody-independent, part of innate immunity.
Lectin (mannan-binding lectin) pathway: mannan-binding lectin (MBL) or ficolins bind mannose residues on microbial surfaces, activating MBL-associated serine proteases (MASP-1/2), which cleave C4 and C2 like the classical pathway - also antibody-independent (Roitt's Essential Immunology; Cellular and Molecular Immunology; Henry's Clinical Diagnosis, p. Mannan-Binding Lectin Pathway).

All three pathways generate C3 convertase → C3b, leading to the common terminal pathway (C5 convertase → C5b-9, the MAC).

Biological roles:

Lysis: MAC punches holes in microbial/cell membranes causing osmotic lysis
Opsonization: C3b/C4b coat pathogens, enhancing phagocytosis via complement receptors
Chemotaxis/inflammation: C3a and C5a are anaphylatoxins that recruit neutrophils/macrophages and increase vascular permeability
Immune complex clearance: solubilizes and helps clear circulating immune complexes
Bridging innate and adaptive immunity: C3d bound to antigen enhances B-cell activation via CR2

7. Why is secondary immune response more rapid than primary? (Korba)

Same mechanism as Q1: the primary response requires naive lymphocyte priming, clonal expansion, and differentiation (lag of 5-10 days, low-titer IgM). The secondary response draws on a pre-existing, expanded pool of long-lived memory B and T cells with higher numbers, lower activation threshold, and affinity-matured receptors, so activation, proliferation, and antibody secretion (predominantly high-affinity IgG) occur within 1-3 days (Medical Microbiology 9e; Park's PSM, "immunological memory").

8. Presence of IgM in fetus/newborn indicates intrauterine infection - why? (Raigarh)

IgM is a large pentameric molecule (~970 kDa) that cannot cross the placenta due to its size, unlike IgG which is actively transported across the placenta via the neonatal Fc receptor. Therefore, any IgM detected in fetal or neonatal blood must have been synthesized by the fetus itself, implying that the fetal immune system was exposed to and responded to an antigen/pathogen in utero - i.e., congenital/intrauterine infection (e.g., TORCH infections, congenital rubella syndrome, congenital syphilis, toxoplasmosis) (Jawetz Melnick & Adelberg's Medical Microbiology 28E; Park's PSM, Congenital Rubella Syndrome).

9. Why is passive immunity short-lived? (SSIMS)

Passive immunity involves the transfer of preformed antibodies (from another person, animal, or pooled immunoglobulin/antiserum) rather than active stimulation of the recipient's own immune system. Because there is no antigenic stimulation of the host's B and T lymphocytes, no memory cells are generated. The transferred antibody is a finite, non-replenished pool that is gradually catabolized/cleared according to its normal biological half-life (IgG ~21-23 days). Once it is degraded, protection ends, and there is no capacity for an anamnestic response - hence protection is immediate but short-lived (typically weeks) (Harrison's Principles of Internal Medicine 22E; Cellular and Molecular Immunology; Janeway's Immunobiology 10e).

11. CMI and AMT (Antibody-Mediated/Humoral Immunity) are independent - is this true?

This statement is actually a half-truth/commonly tested trick: cell-mediated immunity (CMI, driven by T lymphocytes - CD4 helper and CD8 cytotoxic cells) and humoral (antibody-mediated, AMT) immunity are distinct arms of adaptive immunity that can be selectively transferred (historically, humoral immunity is transferable by serum/antibody alone, CMI by transfer of lymphocytes alone - this is the classical evidence for their "independence"), and they act on different targets: humoral immunity acts mainly on extracellular pathogens/free virions/toxins via antibody, while CMI acts on intracellular pathogens (virus-infected cells, intracellular bacteria, tumor cells) via cytotoxic T cells and macrophage activation.

However, they are not functionally isolated in vivo - CD4+ helper T cells (a CMI component) are required for B-cell activation, class switching, and affinity maturation (T-dependent antibody response), so the two systems are interconnected and cooperate, even though they can be demonstrated separately by adoptive transfer experiments (Medical Microbiology 9e, Antigen-Specific Immunity; Cellular and Molecular Immunology, Overview of Humoral and Cell-Mediated Immunity).

12. How do activated Cytotoxic T Lymphocytes (CTLs) induce target cell death? (RIMS)

CD8+ CTLs recognize antigenic peptides presented on MHC class I of infected/abnormal target cells and kill via cell-to-cell contact through two main mechanisms:

Granule exocytosis (perforin-granzyme pathway): Upon forming an immune synapse, the CTL releases cytotoxic granules containing perforin, which polymerizes and forms pores in the target cell membrane, and granzymes (serine proteases, especially granzyme B), which enter through these pores and activate caspases, triggering apoptosis of the target cell.
Fas-FasL pathway: CTLs express Fas ligand (FasL/CD95L), which binds Fas (CD95) on the target cell surface, activating the death receptor pathway and caspase cascade, again leading to apoptosis.

Both mechanisms cause the target cell to die by programmed apoptosis rather than lysis, minimizing release of intracellular pathogens and inflammatory damage (Comprehensive Clinical Nephrology; Cellular and Molecular Immunology, Killing of Target Cells by CTLs; Roitt's Essential Immunology).

13. How is passive immunoprophylaxis useful for post-exposure prophylaxis (PEP)? (RIMS)

Active immunization (vaccination) takes days to weeks to generate protective antibody levels because it depends on primary immune activation. In situations where immediate protection is needed after known/suspected exposure to a pathogen or toxin (e.g., rabies exposure, tetanus-prone wound in an unimmunized person, hepatitis B exposure in a neonate born to HBsAg-positive mother, varicella exposure in an immunocompromised patient, snake/scorpion envenomation), there is no time to wait for active immunity to develop.

Passive immunoprophylaxis (human rabies immunoglobulin, tetanus immunoglobulin, hepatitis B immunoglobulin, varicella-zoster immunoglobulin, anti-venom) supplies ready-made, high-titer specific antibody that provides instant neutralization/protection against the pathogen or toxin during the window before the person's own active immune response (often given simultaneously as combined passive + active immunization, e.g., rabies Ig + rabies vaccine) can mount protective immunity. This bridges the gap until active immunity develops, after which the passively transferred antibody is catabolized (Red Book 2021, Management of Postexposure Prophylaxis).

A quick note: questions 5 and 10 (BCG) and questions 1/7 and 9 (memory/passive immunity) are essentially duplicate questions appearing across different colleges, so the same model answer applies to each.

Recent evidence check: I ran a targeted search for meta-analyses/systematic reviews (last 2 years) on these core immunology concepts (BCG safety in immunocompromised hosts, complement pathway biology, CTL killing mechanisms) - these are established, stable physiology/immunology principles rather than areas of active controlled-trial revision, so no contradicting recent evidence was found that would change these textbook-based answers.

IMG_1007.jpg

Answer diagnosis

Asking for Preferences

Your image has several clinical vignettes. Which one's diagnosis do you want answered?

This is a shared conversation. Sign in to Orris to start your own chat.